Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study

2018/05/04 by Eduardo Vilar‐Gómez, Eduardo Vilar-Gomez, Luis Calzadilla-Bertot +25 · 32 citations
Medicine · #Liver Disease Diagnosis and Treatment #Liver Disease and Transplantation #Hepatitis C virus research

paper · doi:10.1053/j.gastro.2018.04.034

Cited by

• Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
• The potential for primary and secondary prevention of liver cancer death in Australians with alcohol-related liver disease or metabolic-associated steatotic liver disease: A modelling study
• Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study
• Evaluating Semi-Markov Processes and Other Epidemiological Time-to-Event Models by Computing Disease Sojourn Density as Partial Differential Equations
• A Health Economic Evaluation of Routine Hepatocellular Carcinoma Surveillance for People with Compensated Cirrhosis to Support Australian Clinical Guidelines
• MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
• A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
• Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. [europepmc]
• Nonalcoholic Fatty Liver Disease and Obesity Treatment. [europepmc]
• A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). [europepmc]
• The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH. [europepmc]
• NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. [europepmc]
• Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. [europepmc]
• Lifestyle modification in NAFLD/NASH: Facts and figures. [europepmc]
• Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. [europepmc]
• Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. [europepmc]
• Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis. [europepmc]
• Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases. [europepmc]
• The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. [europepmc]
• NAFLD and cardiovascular diseases: a clinical review. [europepmc]
• Liver fibrosis: Pathophysiology and clinical implications. [europepmc]
• Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. [europepmc]
• The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. [europepmc]
• Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. [europepmc]
• Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. [europepmc]
• Current therapies and new developments in NASH. [europepmc]
• NAFLD: Mechanisms, Treatments, and Biomarkers. [europepmc]
• An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis. [europepmc]
• The exposome and liver disease - how environmental factors affect liver health. [europepmc]
• An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. [europepmc]
• Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD. [europepmc]
• Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050. [europepmc]